Pharvaris

Late-stage clinical biopharma developing oral small-molecule bradykinin B2 receptor antagonists (PHA121) for bradykinin-mediated diseases, led by hereditary angioedema (HAE) program; Nasdaq-listed (PHVS) with offices in Netherlands and Switzerland